Last reviewed · How we verify
Ciclesonide HFA
Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, which binds to glucocorticoid receptors in the cytoplasm, leading to anti-inflammatory effects.
Ciclesonide is a prodrug that is converted to its active metabolite, des-ciclesonide, which binds to glucocorticoid receptors in the cytoplasm, leading to anti-inflammatory effects. Used for Asthma.
At a glance
| Generic name | Ciclesonide HFA |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | inhaled corticosteroid |
| Target | glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Upon inhalation, ciclesonide is converted by esterases in the airway epithelium to des-ciclesonide, which then binds to intracellular glucocorticoid receptors, modulating the transcription of genes involved in inflammation.
Approved indications
- Asthma
Common side effects
- Pharyngitis
- Nasal congestion
Key clinical trials
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) (PHASE4)
- A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma (PHASE3)
- Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602) (PHASE2)
- Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408) (PHASE3)
- Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (PHASE3)
- Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis (PHASE3)
- Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |